BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5:e1163462. [PMID: 27471638 DOI: 10.1080/2162402x.2016.1163462] [Cited by in Crossref: 168] [Cited by in F6Publishing: 95] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Siefker-radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. European Urology 2022. [DOI: 10.1016/j.eururo.2022.05.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Barber FD. Adverse Events of Oncologic Immunotherapy and Their Management. Asia Pac J Oncol Nurs 2019;6:212-26. [PMID: 31259216 DOI: 10.4103/apjon.apjon_6_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ritter B, Greten FR. Modulating inflammation for cancer therapy. J Exp Med 2019;216:1234-43. [PMID: 31023715 DOI: 10.1084/jem.20181739] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
4 Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, Ravindranathan R, Kowalsky SJ, Obermajer N, Kammula US, Lee AJH, Lotze MT, Guo ZS, Bartlett DL. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther 2021;28:98-111. [PMID: 32632271 DOI: 10.1038/s41417-020-0189-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Hernandez R, Toomer KH, Põder J, Santos Savio A, Hsiung S, Malek TR. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity. Cancer Immunol Immunother 2021;70:909-21. [PMID: 33037893 DOI: 10.1007/s00262-020-02722-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zawit M, Swami U, Awada H, Arnouk J, Milhem M, Zakharia Y. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med 2021;9:1038. [PMID: 34277838 DOI: 10.21037/atm-21-491] [Reference Citation Analysis]
7 Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, Jesenofsky R, Masamune A, Roeyen G, Pauwels P, Lardon F, Peeters M, Smits ELJ. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget. 2017;8:56968-56979. [PMID: 28915646 DOI: 10.18632/oncotarget.18185] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
8 Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ. Improving Immunotherapy Through Glycodesign. Front Immunol 2018;9:2485. [PMID: 30450094 DOI: 10.3389/fimmu.2018.02485] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
9 Chun BM, Page DB, Mcarthur HL. Combination Immunotherapy Strategies in Breast Cancer. Curr Breast Cancer Rep 2019;11:228-40. [DOI: 10.1007/s12609-019-00333-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg KJ. Deciphering Natural Killer Cell Homeostasis. Front Immunol 2020;11:812. [PMID: 32477340 DOI: 10.3389/fimmu.2020.00812] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Mukherjee S. Genomics-Guided Immunotherapy for Precision Medicine in Cancer. Cancer Biother Radiopharm 2019;34:487-97. [PMID: 31314580 DOI: 10.1089/cbr.2018.2758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
12 Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology 2017;6:e1363139. [PMID: 29147628 DOI: 10.1080/2162402X.2017.1363139] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
13 Ren J, Chu AE, Jude KM, Picton LK, Kare AJ, Su L, Montano Romero A, Huang PS, Garcia KC. Interleukin-2 superkines by computational design. Proc Natl Acad Sci U S A 2022;119:e2117401119. [PMID: 35294290 DOI: 10.1073/pnas.2117401119] [Reference Citation Analysis]
14 MacDonald A, Lam B, Lin J, Ferrall L, Kung YJ, Tsai YC, Wu TC, Hung CF. Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells. Front Immunol 2021;12:755995. [PMID: 34804041 DOI: 10.3389/fimmu.2021.755995] [Reference Citation Analysis]
15 Hoogstad-van Evert J, Paap R, Nap A, van der Molen R. The Promises of Natural Killer Cell Therapy in Endometriosis. Int J Mol Sci 2022;23:5539. [PMID: 35628346 DOI: 10.3390/ijms23105539] [Reference Citation Analysis]
16 Qiu Q, Lin Y, Ma Y, Li X, Liang J, Chen Z, Liu K, Huang Y, Luo H, Huang R, Luo L. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. Front Immunol 2020;11:612202. [PMID: 33488618 DOI: 10.3389/fimmu.2020.612202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Bruins WSC, Zweegman S, Mutis T, van de Donk NWCJ. Targeted Therapy With Immunoconjugates for Multiple Myeloma. Front Immunol 2020;11:1155. [PMID: 32636838 DOI: 10.3389/fimmu.2020.01155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
18 Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, Zhong W, Lu Y, Ding Y, Lu Q, Ye F, Hua H. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Front Immunol 2020;11:622509. [PMID: 33633741 DOI: 10.3389/fimmu.2020.622509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
19 Baptista B, Carapito R, Laroui N, Pichon C, Sousa F. mRNA, a Revolution in Biomedicine. Pharmaceutics 2021;13:2090. [PMID: 34959371 DOI: 10.3390/pharmaceutics13122090] [Reference Citation Analysis]
20 Li R, Johnson R, Yu G, McKenna DH, Hubel A. Preservation of cell-based immunotherapies for clinical trials. Cytotherapy 2019;21:943-57. [PMID: 31416704 DOI: 10.1016/j.jcyt.2019.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
21 Chulpanova DS, Solovyeva VV, James V, Arkhipova SS, Gomzikova MO, Garanina EE, Akhmetzyanova ER, Tazetdinova LG, Khaiboullina SF, Rizvanov AA. Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro. Bioengineering (Basel) 2020;7:E59. [PMID: 32560387 DOI: 10.3390/bioengineering7020059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Tan E, Gakhar N, Kirtane K. TCR gene-engineered cell therapy for solid tumors. Best Pract Res Clin Haematol 2021;34:101285. [PMID: 34625228 DOI: 10.1016/j.beha.2021.101285] [Reference Citation Analysis]
23 Shaker MA, Doré JJE, Younes HM. Controlled release of bioactive IL-2 from visible light photocured biodegradable elastomers for cancer immunotherapy applications. Pharm Dev Technol 2021;:1-12. [PMID: 34927547 DOI: 10.1080/10837450.2021.2019764] [Reference Citation Analysis]
24 Tiriveedhi V, Ivy MT, Myles EL, Zent R, Rathmell JC, Titze J. Ex Vivo High Salt Activated Tumor-Primed CD4+T Lymphocytes Exert a Potent Anti-Cancer Response. Cancers (Basel) 2021;13:1690. [PMID: 33918403 DOI: 10.3390/cancers13071690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol 2021;12:669474. [PMID: 34012451 DOI: 10.3389/fimmu.2021.669474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 D'mello KP, Zhao L, Kaser EC, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of interleukins and the widely studied TNF-α in non-Hodgkin's lymphoma. Med Oncol 2021;38:56. [PMID: 33835307 DOI: 10.1007/s12032-021-01504-y] [Reference Citation Analysis]
27 Chulpanova DS, Gilazieva ZE, Kletukhina SK, Aimaletdinov AM, Garanina EE, James V, Rizvanov AA, Solovyeva VV. Cytochalasin B-Induced Membrane Vesicles from Human Mesenchymal Stem Cells Overexpressing IL2 Are Able to Stimulate CD8+ T-Killers to Kill Human Triple Negative Breast Cancer Cells. Biology (Basel) 2021;10:141. [PMID: 33579033 DOI: 10.3390/biology10020141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lange C, Machado Weber A, Schmidt R, Schroeder C, Strowitzki T, Germeyer A. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line. PLoS One 2021;16:e0248103. [PMID: 33690729 DOI: 10.1371/journal.pone.0248103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Alfarra H, Weir J, Grieve S, Reiman T. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Front Immunol 2020;11:575609. [PMID: 33304346 DOI: 10.3389/fimmu.2020.575609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Eriau E, Paillet J, Kroemer G, Pol JG. Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy. Cancers (Basel) 2021;13:1260. [PMID: 33809187 DOI: 10.3390/cancers13061260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs 2021;13:1913791. [PMID: 33974508 DOI: 10.1080/19420862.2021.1913791] [Reference Citation Analysis]
32 Fernandes CD, Arriaga MB, Costa MCM, Costa MCM, Costa MHM, Vinhaes CL, Silveira-Mattos PS, Fukutani KF, Andrade BB. Host Inflammatory Biomarkers of Disease Severity in Pediatric Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Open Forum Infect Dis 2019;6:ofz520. [PMID: 31867405 DOI: 10.1093/ofid/ofz520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Levitzki A, Klein S. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. Proc Natl Acad Sci U S A 2019;116:11579-86. [PMID: 31076554 DOI: 10.1073/pnas.1816012116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, Yamashita S, Katsuda M, Hayata A, Akamatsu H, Jinnin M, Hara I, Yamaue H, Akamizu T. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci 2020;111:1468-77. [PMID: 32086984 DOI: 10.1111/cas.14363] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
35 El-Ashmawy NE, El-Zamarany EA, Khedr EG, El-Bahrawy HA, El-Feky OA. Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study. Clin Exp Med 2018;18:535-46. [PMID: 30062618 DOI: 10.1007/s10238-018-0521-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Li J, Che L, Xu C, Lu D, Xu Y, Liu M, Chai W. XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8 + T cells. Journal of Receptors and Signal Transduction. [DOI: 10.1080/10799893.2021.2019274] [Reference Citation Analysis]
37 Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. Int J Mol Sci 2018;19:E2922. [PMID: 30261606 DOI: 10.3390/ijms19102922] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
38 Petitprez F, Ayadi M, de Reyniès A, Fridman WH, Sautès-Fridman C, Job S. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:643065. [PMID: 33996558 DOI: 10.3389/fonc.2021.643065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shen S, Sckisel G, Sahoo A, Lalani A, Otter DD, Pearson J, DeVoss J, Cheng J, Casey SC, Case R, Yang M, Low R, Daris M, Fan B, Agrawal NJ, Ali K. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity. Front Immunol 2020;11:832. [PMID: 32457754 DOI: 10.3389/fimmu.2020.00832] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol 2022;13:835762. [PMID: 35309357 DOI: 10.3389/fimmu.2022.835762] [Reference Citation Analysis]
41 Sasso E, D'Avino C, Passariello M, D'Alise AM, Siciliano D, Esposito ML, Froechlich G, Cortese R, Scarselli E, Zambrano N, Nicosia A, De Lorenzo C. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. MAbs 2018;10:1060-72. [PMID: 29995563 DOI: 10.1080/19420862.2018.1496772] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
42 An X, Varadarajan N. Single-cell technologies for profiling T cells to enable monitoring of immunotherapies. Curr Opin Chem Eng 2018;19:142-52. [PMID: 31131208 DOI: 10.1016/j.coche.2018.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
43 Przybyla A, Lehmann AA, Zhang T, Mackiewicz J, Galus Ł, Kirchenbaum GA, Mackiewicz A, Lehmann PV. Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization. Cancers (Basel) 2021;13:E223. [PMID: 33435427 DOI: 10.3390/cancers13020223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Atitey K, Anchang B. Mathematical Modeling of Proliferative Immune Response Initiated by Interactions Between Classical Antigen-Presenting Cells Under Joint Antagonistic IL-2 and IL-4 Signaling. Front Mol Biosci 2022;9:777390. [DOI: 10.3389/fmolb.2022.777390] [Reference Citation Analysis]
45 Roelants C, Pillet C, Franquet Q, Sarrazin C, Peilleron N, Giacosa S, Guyon L, Fontanell A, Fiard G, Long JA, Descotes JL, Cochet C, Filhol O. Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. Cancers (Basel) 2020;12:E232. [PMID: 31963500 DOI: 10.3390/cancers12010232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
46 Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol 2021;14:78. [PMID: 33980266 DOI: 10.1186/s13045-021-01085-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Tubin S, Gupta S, Grusch M, Popper HH, Brcic L, Ashdown ML, Khleif SN, Peter-Vörösmarty B, Hyden M, Negrini S, Fossati P, Hug E. Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY). Cancers (Basel) 2020;13:E50. [PMID: 33375357 DOI: 10.3390/cancers13010050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Wang X, Li X, Ito A, Sogo Y, Ohno T. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site. Acta Biomater 2022;145:235-45. [PMID: 35398544 DOI: 10.1016/j.actbio.2022.04.001] [Reference Citation Analysis]
49 Lim J, Cho E, Lee K, Choi Y, Seo Y, Jeon H, Choi J. Current Immunotherapy Approaches for Malignant Melanoma. BioChip J 2019;13:105-14. [DOI: 10.1007/s13206-019-3108-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
50 Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V, Ben-Eliyahu S. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol 2020;17:313-26. [PMID: 32066936 DOI: 10.1038/s41571-019-0319-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
51 Jo H, Cha B, Kim H, Brito S, Kwak BM, Kim ST, Bin BH, Lee MG. α-Pinene Enhances the Anticancer Activity of Natural Killer Cells via ERK/AKT Pathway. Int J Mol Sci 2021;22:E656. [PMID: 33440866 DOI: 10.3390/ijms22020656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
52 Frutoso M, Mortier E. NK Cell Hyporesponsiveness: More Is Not Always Better. Int J Mol Sci 2019;20:E4514. [PMID: 31547251 DOI: 10.3390/ijms20184514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
53 Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood 2017;130:2410-9. [PMID: 29042364 DOI: 10.1182/blood-2017-04-777052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
54 Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 2021;6:424. [PMID: 34924562 DOI: 10.1038/s41392-021-00827-6] [Reference Citation Analysis]
55 Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers (Basel) 2019;11:E971. [PMID: 31336704 DOI: 10.3390/cancers11070971] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
56 Lamichhane P, Maiolini M, Alnafoosi O, Hussein S, Alnafoosi H, Umbela S, Richardson T, Alla N, Lamichhane N, Subhadra B, Deshmukh RR. Colorectal Cancer and Probiotics: Are Bugs Really Drugs? Cancers (Basel) 2020;12:E1162. [PMID: 32380712 DOI: 10.3390/cancers12051162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
57 Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 2020;13:84. [PMID: 32600470 DOI: 10.1186/s13045-020-00922-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
58 Sanseviero E. NK Cell-Fc Receptors Advance Tumor Immunotherapy. J Clin Med 2019;8:E1667. [PMID: 31614774 DOI: 10.3390/jcm8101667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
59 Han L, Jiang Q, Yao W, Fu T, Zeng Q. Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients. BMC Cancer 2018;18:725. [PMID: 29980186 DOI: 10.1186/s12885-018-4581-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Kan T, Feldman E, Timaner M, Raviv Z, Shen-Orr S, Aronheim A, Shaked Y. IL-31 induces antitumor immunity in breast carcinoma. J Immunother Cancer 2020;8:e001010. [PMID: 32843492 DOI: 10.1136/jitc-2020-001010] [Reference Citation Analysis]
61 Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-sanea MM, Althobaiti H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol 2022;10:797440. [DOI: 10.3389/fbioe.2022.797440] [Reference Citation Analysis]
62 Lopes A, Feola S, Ligot S, Fusciello M, Vandermeulen G, Préat V, Cerullo V. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. J Immunother Cancer 2019;7:174. [PMID: 31291991 DOI: 10.1186/s40425-019-0644-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 Ottolenghi A, Bolel P, Sarkar R, Greenshpan Y, Iraqi M, Ghosh S, Bhattacharya B, Taylor ZV, Kundu K, Radinsky O, Gazit R, Stepensky D, Apte RN, Voronov E, Porgador A. Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. Sci Rep 2021;11:7676. [PMID: 33828163 DOI: 10.1038/s41598-021-87102-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhou X, Qu M, Tebon P, Jiang X, Wang C, Xue Y, Zhu J, Zhang S, Oklu R, Sengupta S, Sun W, Khademhosseini A. Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Adv Sci (Weinh) 2020;7:2001447. [PMID: 33042756 DOI: 10.1002/advs.202001447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
65 Cha HR, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Res 2020;80:1615-23. [PMID: 32066566 DOI: 10.1158/0008-5472.CAN-19-2948] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
66 Gupta VK, Kumar A. Targeting lysophosphatidic acid receptor with Ki16425 impedes T cell lymphoma progression through apoptosis induction, glycolysis inhibition, and activation of antitumor immune response. Apoptosis 2022. [PMID: 35366141 DOI: 10.1007/s10495-022-01723-2] [Reference Citation Analysis]
67 Zwart ES, Yüksel E, Pannekoek A, de Vries R, Mebius RE, Kazemier G. De Novo Carcinoma after Solid Organ Transplantation to Give Insight into Carcinogenesis in General-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1122. [PMID: 33807849 DOI: 10.3390/cancers13051122] [Reference Citation Analysis]
68 Phung SK, Miller JS, Felices M. Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. Mol Diagn Ther 2021;25:577-92. [PMID: 34327614 DOI: 10.1007/s40291-021-00550-6] [Reference Citation Analysis]
69 Lasek W, Zapała Ł. Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology. Cent European J Urol 2021;74:300-7. [PMID: 34729217 DOI: 10.5173/ceju.2021.0094] [Reference Citation Analysis]
70 Pinheiro PF, Justino GC, Marques MM. NKp30 - A prospective target for new cancer immunotherapy strategies. Br J Pharmacol 2020;177:4563-80. [PMID: 32737988 DOI: 10.1111/bph.15222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
71 Han NR, Kim KC, Kim JS, Ko SG, Park HJ, Moon PD. The immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) or its active constituent nodakenin. J Ethnopharmacol 2022;285:114893. [PMID: 34875347 DOI: 10.1016/j.jep.2021.114893] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Khan M, Maker AV, Jain S. The Evolution of Cancer Immunotherapy. Vaccines (Basel) 2021;9:614. [PMID: 34200997 DOI: 10.3390/vaccines9060614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Liu M, Guo F. Recent updates on cancer immunotherapy. Prec Clin Med. 2018;1:65-74. [PMID: 30687562 DOI: 10.1093/pcmedi/pby011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
74 Qin Y, Lee Y, Seo J, Kim T, Shin JH, Park SH. NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs. Front Immunol 2019;10:761. [PMID: 31031760 DOI: 10.3389/fimmu.2019.00761] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Chen W, Chen Q, Chen Q, Cui C, Duan S, Kang Y, Liu Y, Liu Y, Muhammad W, Shao S, Tang C, Wang J, Wang L, Xiong M, Yin L, Zhang K, Zhang Z, Zhen X, Feng J, Gao C, Gu Z, He C, Ji J, Jiang X, Liu W, Liu Z, Peng H, Shen Y, Shi L, Sun X, Wang H, Wang J, Xiao H, Xu F, Zhong Z, Zhang X, Chen X. Biomedical polymers: synthesis, properties, and applications. Sci China Chem . [DOI: 10.1007/s11426-022-1243-5] [Reference Citation Analysis]
76 Menon N, Dang HX, Datla US, Moarefian M, Lawrence CB, Maher CA, Jones CN. Heparin-based hydrogel scaffolding alters the transcriptomic profile and increases the chemoresistance of MDA-MB-231 triple-negative breast cancer cells. Biomater Sci 2020;8:2786-96. [PMID: 32091043 DOI: 10.1039/c9bm01481k] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Shafique QUA, Rehman HM, Zaheer T, Tahir RA, Bhinder MA, Gul R, Saleem M. A Computational Approach to Modeling an Antagonistic Angiogenic VEGFR1-IL2 Fusion Protein for Cancer Therapy. Bioinform Biol Insights 2021;15:11779322211043297. [PMID: 34566410 DOI: 10.1177/11779322211043297] [Reference Citation Analysis]
78 Razeghian E, Margiana R, Chupradit S, Bokov DO, Abdelbasset WK, Marofi F, Shariatzadeh S, Tosan F, Jarahian M. Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy. Front Med (Lausanne) 2021;8:721174. [PMID: 34513882 DOI: 10.3389/fmed.2021.721174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Tsai YT, Liang CH, Yu JH, Huang KC, Tung CH, Wu JE, Wu YY, Chang CH, Hong TM, Chen YL. A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer. Mol Ther Nucleic Acids 2019;18:991-8. [PMID: 31778957 DOI: 10.1016/j.omtn.2019.10.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
80 Fan L, Xu G, Cao J, Li M, Zhang H, Li F, Qi X, Zhang X, Li Z, Han P, Yang X. Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers (Basel) 2021;13:5574. [PMID: 34771735 DOI: 10.3390/cancers13215574] [Reference Citation Analysis]
81 Lorenzo-Herrero S, López-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, Gonzalez S. NK Cell-Based Immunotherapy in Cancer Metastasis. Cancers (Basel) 2018;11:E29. [PMID: 30597841 DOI: 10.3390/cancers11010029] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
82 Cui JY, Lisi GP. Molecular Level Insights Into the Structural and Dynamic Factors Driving Cytokine Function. Front Mol Biosci 2021;8:773252. [PMID: 34760929 DOI: 10.3389/fmolb.2021.773252] [Reference Citation Analysis]
83 Gonzalez Segura G, Cantelli BA, Peronni K, Rodrigo Sanches P, Komoto TT, Rizzi E, Beleboni RO, Junior WADS, Martinez-Rossi NM, Marins M, Fachin AL. Cellular and Molecular Response of Macrophages THP-1 during Co-Culture with Inactive Trichophyton rubrum Conidia. J Fungi (Basel) 2020;6:E363. [PMID: 33322794 DOI: 10.3390/jof6040363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11:39. [PMID: 29544515 DOI: 10.1186/s13045-018-0582-8] [Cited by in Crossref: 285] [Cited by in F6Publishing: 280] [Article Influence: 71.3] [Reference Citation Analysis]
85 Dong X, Jia Z, Yu B, Zhang X, Xu F, Tan L. Effect of intersphincteric fistula tract ligation versus anal fistulectomy on pain scores and serum levels of vascular endothelial growth factor and interleukin-2 in patients with simple anal fistulas. J Int Med Res 2020;48:300060520949072. [PMID: 32967495 DOI: 10.1177/0300060520949072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Sordo-Bahamonde C, Vitale M, Lorenzo-Herrero S, López-Soto A, Gonzalez S. Mechanisms of Resistance to NK Cell Immunotherapy. Cancers (Basel) 2020;12:E893. [PMID: 32272610 DOI: 10.3390/cancers12040893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
87 Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, Gangula PR, Pandey MK, Durden DL, Byrareddy SN, Challagundla KB. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics 2021;11:731-53. [PMID: 33391502 DOI: 10.7150/thno.51471] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 24.0] [Reference Citation Analysis]
88 Yang M, Chen G, Gao K, Wang Y. Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications. Front Oncol 2021;11:622752. [PMID: 33796460 DOI: 10.3389/fonc.2021.622752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Gaudino SJ, Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front Immunol 2019;10:360. [PMID: 30894857 DOI: 10.3389/fimmu.2019.00360] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 20.3] [Reference Citation Analysis]
90 Mahhengam N, Kazemnezhad K, Setia Budi H, Ansari MJ, Olegovich Bokov D, Suksatan W, Thangavelu L, Siahmansouri H. Targeted therapy of tumor microenvironment by gold nanoparticles as a new therapeutic approach. Journal of Drug Targeting. [DOI: 10.1080/1061186x.2022.2032095] [Reference Citation Analysis]
91 Suraya R, Nagano T, Kobayashi K, Nishimura Y. Microbiome as a Target for Cancer Therapy. Integr Cancer Ther 2020;19:1534735420920721. [PMID: 32564632 DOI: 10.1177/1534735420920721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Dong J, Chen H. Cardiotoxicity of Anticancer Therapeutics. Front Cardiovasc Med 2018;5:9. [PMID: 29473044 DOI: 10.3389/fcvm.2018.00009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 9.5] [Reference Citation Analysis]
93 Wang HY, Chang YC, Hu CW, Kao CY, Yu YA, Lim SK, Mou KY. Development of a Novel Cytokine Vehicle Using Filamentous Phage Display for Colorectal Cancer Treatment. ACS Synth Biol 2021;10:2087-95. [PMID: 34342970 DOI: 10.1021/acssynbio.1c00266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Wu J, Wang YC, Xu WH, Luo WJ, Wan FN, Zhang HL, Ye DW, Qu YY, Zhu YP. High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma. Onco Targets Ther 2020;13:10453-64. [PMID: 33116625 DOI: 10.2147/OTT.S272553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
95 K S, S L. Antimetastatic Potential of Garcinone E in Human Oral Cancer Cells. Asian Pac J Cancer Prev 2019;20:65-72. [PMID: 30678382 DOI: 10.31557/APJCP.2019.20.1.65] [Reference Citation Analysis]
96 Boss MK, Watts R, Harrison LG, Hopkins S, Chow L, Trageser E, Easton C, LaRue SM, Regan D, Dewhirst MW, Dow S. Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy. Int J Mol Sci 2022;23:826. [PMID: 35055015 DOI: 10.3390/ijms23020826] [Reference Citation Analysis]
97 Coventry BJ. Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. Ther Adv Vaccines Immunother 2019;7:2515135519862234. [PMID: 31414074 DOI: 10.1177/2515135519862234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
98 Jin D, Jiang Y, Chang L, Wei J, Sun J. New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases. Int Immunopharmacol 2022;110:108935. [PMID: 35732097 DOI: 10.1016/j.intimp.2022.108935] [Reference Citation Analysis]
99 Quixabeira DCA, Zafar S, Santos JM, Cervera-Carrascon V, Havunen R, Kudling TV, Basnet S, Anttila M, Kanerva A, Hemminki A. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Front Immunol 2021;12:674400. [PMID: 34084172 DOI: 10.3389/fimmu.2021.674400] [Reference Citation Analysis]
100 Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, Zhuang S, Daman AW, Chiu EY, Bates BM, Greenberg PD. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J Exp Med 2020;217:e20191166. [PMID: 32860705 DOI: 10.1084/jem.20191166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
101 Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med 2019;11:eaau3259. [PMID: 30971453 DOI: 10.1126/scitranslmed.aau3259] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 30.5] [Reference Citation Analysis]
102 Xu Y, Pan Y, Zhou Z. Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model. J Thorac Dis 2019;11:4671-81. [PMID: 31903256 DOI: 10.21037/jtd.2019.10.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Pfefferle A, Huntington ND. You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. Cancers (Basel) 2020;12:E706. [PMID: 32192067 DOI: 10.3390/cancers12030706] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
104 Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy. Mol Cancer 2021;20:69. [PMID: 33858437 DOI: 10.1186/s12943-021-01348-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
105 Sahu M, Suryawanshi H. Immunotherapy: The future of cancer treatment. J Oral Maxillofac Pathol 2021;25:371. [PMID: 34703141 DOI: 10.4103/0973-029X.325257] [Reference Citation Analysis]
106 Zekri ARN, El Deeb S, Bahnassy AA, Badr AM, Abdellateif MS, Esmat G, Salama H, Mohanad M, El-dien AE, Rabah S, Abd Elkader A. Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. World J Gastroenterol 2018; 24(11): 1228-1238 [PMID: 29568203 DOI: 10.3748/wjg.v24.i11.1228] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
107 Singh A, Dhume K, Tejero JD, Strutt TM, McKinstry KK. CD122-targetted IL-2 signals cause acute and selective apoptosis of B cells in Peyer's Patches. Sci Rep 2020;10:12668. [PMID: 32728053 DOI: 10.1038/s41598-020-69632-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Reference Citation Analysis]
109 Inoue T, Byrne T, Inoue M, Tait ME, Wall P, Wang A, Dermyer MR, Laklai H, Binder JJ, Lees C, Hollingsworth R, Maruri-Avidal L, Kirn DH, McDonald DM. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing. Mol Cancer Ther 2021;20:1481-94. [PMID: 34045231 DOI: 10.1158/1535-7163.MCT-20-0863] [Reference Citation Analysis]
110 Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther 2017;17:889-904. [PMID: 28780888 DOI: 10.1080/14737140.2017.1364995] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]
111 Nash A, Aghlara-Fotovat S, Hernandez A, Scull C, Veiseh O. Clinical translation of immunomodulatory therapeutics. Adv Drug Deliv Rev 2021;176:113896. [PMID: 34324885 DOI: 10.1016/j.addr.2021.113896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
112 Li Z, Wang C, Deng H, Wu J, Huang H, Sun R, Zhang H, Xiong X, Feng M. Robust Photodynamic Therapy Using 5-ALA-Incorporated Nanocomplexes Cures Metastatic Melanoma through Priming of CD4+CD8+ Double Positive T Cells. Adv Sci (Weinh) 2019;6:1802057. [PMID: 30886812 DOI: 10.1002/advs.201802057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
113 Bte Syed Sulaiman N, Kuick CH, Chang KTE, Wan KR, Looi WS, Low DCY, Seow WT, Low SYY. Cytokines in Pediatric Pilocytic Astrocytomas: A Clinico-Pathological Study. NeuroSci 2021;2:95-108. [DOI: 10.3390/neurosci2010006] [Reference Citation Analysis]
114 Granhøj JS, Witness Præst Jensen A, Presti M, Met Ö, Svane IM, Donia M. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opin Biol Ther 2022. [PMID: 35414331 DOI: 10.1080/14712598.2022.2064711] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Braschi-Amirfarzan M, Tirumani SH, Hodi FS Jr, Nishino M. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol 2017;18:42-53. [PMID: 28096717 DOI: 10.3348/kjr.2017.18.1.42] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
116 Colon-Echevarria CB, Lamboy-Caraballo R, Aquino-Acevedo AN, Armaiz-Pena GN. Neuroendocrine Regulation of Tumor-Associated Immune Cells. Front Oncol 2019;9:1077. [PMID: 31737559 DOI: 10.3389/fonc.2019.01077] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
117 Kupcova Skalnikova H, Cizkova J, Cervenka J, Vodicka P. Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research. Int J Mol Sci 2017;18:E2697. [PMID: 29236046 DOI: 10.3390/ijms18122697] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
118 He J, Ye S, Correia P, Fernandes I, Zhang R, Wu M, Freitas V, Mateus N, Oliveira H. Dietary polyglycosylated anthocyanins, the smart option? A comprehensive review on their health benefits and technological applications. Compr Rev Food Sci Food Saf 2022. [PMID: 35534086 DOI: 10.1111/1541-4337.12970] [Reference Citation Analysis]
119 Suri S, Mitra P, Abhilasha A, Saxena I, Garg MK, Bohra GK, Sharma P. Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus. J Basic Clin Physiol Pharmacol 2021. [PMID: 33711216 DOI: 10.1515/jbcpp-2020-0272] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Galli F, Aguilera JV, Palermo B, Markovic SN, Nisticò P, Signore A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res 2020;39:89. [PMID: 32423420 DOI: 10.1186/s13046-020-01586-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
121 Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol 2021;33:7-15. [PMID: 32496557 DOI: 10.1093/intimm/dxaa037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
122 Ahmed A, Köhler S, Klotz R, Giese N, Lasitschka F, Hackert T, Springfeld C, Zörnig I, Jäger D, Halama N. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma. Oncoimmunology 2021;10:1962135. [PMID: 34408923 DOI: 10.1080/2162402X.2021.1962135] [Reference Citation Analysis]
123 Palata O, Hradilova Podzimkova N, Nedvedova E, Umprecht A, Sadilkova L, Palova Jelinkova L, Spisek R, Adkins I. Radiotherapy in Combination With Cytokine Treatment. Front Oncol 2019;9:367. [PMID: 31179236 DOI: 10.3389/fonc.2019.00367] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
124 Stephen ZR, Zhang M. Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer. Adv Healthc Mater 2021;10:e2001415. [PMID: 33236511 DOI: 10.1002/adhm.202001415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
125 Shi L, Sheng J, Chen G, Zhu P, Shi C, Li B, Park C, Wang J, Zhang B, Liu Z, Yang X. Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance. J Immunother Cancer 2020;8:e000973. [PMID: 33028692 DOI: 10.1136/jitc-2020-000973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]